CMPX: Compass Bio Net earnings per share (EPS TTM)
High demand for targeted immunotherapy is driving the expansion of Compass Therapeutics, and the chart of net profit per share for the last 12 months is available for analysis on GURU.Markets, where the -0.40 mark reflects the latest data. Funding is based on investments and partnerships for antibody development. The absence of debt and the success of the CTX-009 drug make Compass Therapeutics (CMPX) an attractive acquisition target for Big Pharma.
Summary analytical data breakdowns for Compass Therapeutics Inc (CMPX)
- share price and expert price forecast:
- market capitalization information:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Compass Therapeutics|CMPX - Long-Term Debt to Capital|Short-Term Debt to Equity Compass Bio|CMPX - Company Aggregate Debt|Debt to Book Capitalization Ratio Compass Therapeutics, Inc.|CMPX - Long-Term Debt|Company Current Liabilities Compass Therapeutics|Quick Liquidity Indicator compasstherapeutics.com
- earnings and multiples data:
CMPX - Profit After Payment of Taxes|Projected Future Earnings Compass Therapeutics|CMPX - Company Value to Net Income|Forward P/E Multiple Compass Therapeutics, Inc.|CMPX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics, Inc.|CMPX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Compass Therapeutics|CMPX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months compasstherapeutics.com|CMPX - Earnings per share trend in current year|Expected earnings per share growth for next year Compass Therapeutics
Fundamental valuation:CMPX - Compass Therapeutics
High barriers to entry in the cancer immunotherapy segment due to expensive R&D make the analysis of Compass Therapeutics (CMPX) actual earnings critically important. By examining the rolling annual EPS chart, an investor can see the net profit per share over 12 months, which allows them to filter out market noise and determine the fair value of the business relative to its actual earnings.
Main competitors
IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (immunocore.com)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Zymeworks Corp|Net earnings per share for the last 12 months Tango Therapeutics Corp (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics (IOVA)|Net earnings per share for the last 12 months immatics.com IMTX|Xencor - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Group Inc REPL|LYEL - Earnings per share for the last twelve months|IPHA (Innate Pharma S.A) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma)|Earnings per share for the trailing year ALXO|Cue Biopharma, Inc. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months PDS Biotechnology|sonnetbio.com (SONN) - Earnings per share for the last twelve months|MAIA Bio - Earnings per share for the trailing year|LIMN (Liminatus Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Lava Tx|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics Inc (SNSE) - Net earnings per one share for the last twelve months|Theriva Biologics, Inc. - Net earnings per share (EPS TTM)|Gritstone bio, Inc. (GRTS) - Net earnings per share for the last 12 months|Kineta (KA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months NexImmune Inc (NEXI)|Earnings per share for the last twelve months Turnstone Biologics Corp|Net earnings per share for the last 12 months Vaccinex Inc (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)
